CAL Stock Analysis: Caleres | NYSE
Apparel Retail | NYSE, USA | Market Cap: 393m USD | 12M Return: -16.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.54M
EPS Trend: -88.5%
Qual. Beats: 0
Rev. Trend: -59.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Caleres, Inc. (NYSE: CAL) is a U.S.-based footwear company that designs, develops, sources, manufactures, and distributes footwear across the United States, Canada, East and Southeast Asia, and other international markets. Founded in 1878 and headquartered in Saint Louis, Missouri, the company was formerly known as Brown Shoe Company before rebranding to Caleres in May 2015.
The company operates through two business segments: Famous Footwear, its retail chain, and Brand Portfolio, which encompasses its owned and licensed wholesale brands. Its product mix spans licensed, branded, and private-label athletic, casual, and dress footwear, combining third-party labels such as Nike, Skechers, adidas, Crocs, Birkenstock, and New Balance with company-owned brands including Sam Edelman, Vionic, Allen Edmonds, Naturalizer, LifeStride, Franco Sarto, and Rykä.
Caleres runs a diversified, omnichannel distribution model spanning retail shoe stores, wholesale to department stores, mass merchandisers, and online retailers, plus a portfolio of branded e-commerce sites. This dual wholesale-and-retail structure is typical of large footwear players in the Consumer Discretionary / Apparel Retail segment, where hybrid models allow companies to capture margin from owned brands while leveraging retail scale to sell third-party labels.
- Famous Footwear comparable sales drive majority of revenue and earnings
- Hey Dude brand slowdown weighs on Brand Portfolio segment margins
- Asia sourcing exposure raises tariff and freight cost risks
| Net Income: 280k TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.07 > 1.0 |
| NWC/Revenue: 1.04% < 20% (prev 2.84%; Δ -1.80% < -1%) |
| CFO/TA 0.04 > 3% & CFO 81.1m > Net Income 280k |
| Net Debt (1.51b) to EBITDA (67.9m): 22.28 < 3 |
| Current Ratio: 1.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.6m) vs 12m ago -0.02% < -2% |
| Gross Margin: 43.47% > 18% (prev 44.50%; Δ -1.03% > 0.5%) |
| Asset Turnover: 143.0% > 50% (prev 140.4%; Δ 2.66% > 0%) |
| Interest Coverage Ratio: 0.10 > 6 (EBIT TTM 1.93m / Interest Expense TTM 19.4m) |
| A: 0.01 (Total Current Assets 912.6m - Total Current Liabilities 883.2m) / Total Assets 2.02b |
| B: 0.21 (Retained Earnings 430.0m / Total Assets 2.02b) |
| C: 0.00 (EBIT TTM 1.93m / Avg Total Assets 1.96b) |
| D: 0.44 (Book Value of Equity 612.1m / Total Liabilities 1.40b) |
| Altman-Z'' = 1.25 = BB |
| DSRI: 1.03 (Receivables 178.4m/165.1m, Revenue 2.81b/2.68b) |
| GMI: 1.02 (GM 44.50% / 43.47%) |
| AQI: 1.00 (AQ_t 0.17 / AQ_t-1 0.17) |
| SGI: 1.05 (Revenue 2.81b / 2.68b) |
| TATA: -0.04 (NI 280k - CFO 81.1m) / TA 2.02b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of July 12, 2026, the stock is trading at USD 11.81 with a total of 203,768 shares traded. Over the past week, the price has changed by +0.85%, over one month by -13.61%, over three months by -5.19% and over the past year by -16.69%.
Current recommended Stop Loss: 9.80 (which is 17% or 2.5 ATR below the current price).
Caleres has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CAL.
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17 | 43.9% |
P/E Forward = 7.5075
P/S = 0.14
P/B = 0.6799
P/EG = 0.8213
Revenue TTM = 2.81b USD
EBIT TTM = 1.93m USD
EBITDA TTM = 67.9m USD
Long Term Debt = 475.1m USD (estimated: total debt 949.3m - short term 474.2m)
Short Term Debt = 474.2m USD (from shortTermDebt, last quarter)
Debt = 1.55b USD (from shortLongTermDebtTotal, last quarter) + Leases 601.8m
Net Debt = 1.51b USD (calculated: Debt 1.55b - CCE 37.7m)
Enterprise Value = 1.91b USD (393.3m + Debt 1.55b - CCE 37.7m)
Interest Coverage Ratio = 0.10 (Ebit TTM 1.93m / Interest Expense TTM 19.4m)
EV/FCF = 86.52x (Enterprise Value 1.91b / FCF TTM 22.0m)
FCF Yield = 1.16% (FCF TTM 22.0m / Enterprise Value 1.91b)
FCF Margin = 0.78% (FCF TTM 22.0m / Revenue TTM 2.81b)
Net Margin = 0.01% (Net Income TTM 280k / Revenue TTM 2.81b)
Gross Margin = 43.47% ((Revenue TTM 2.81b - Cost of Revenue TTM 1.59b) / Revenue TTM)
Gross Margin QoQ = 47.33% (prev 41.77%)
Tobins Q-Ratio = 0.94 (Enterprise Value 1.91b / Total Assets 2.02b)
Interest Expense / Debt = 1.25% (Interest Expense 19.4m / Debt 1.55b)
Taxrate = 32.44% (6.60m / 20.4m)
NOPAT = 1.30m (EBIT 1.93m * (1 - 32.44%))
Current Ratio = 1.03 (Total Current Assets 912.6m / Total Current Liabilities 883.2m)
Debt / Equity = 2.53 (Debt 1.55b / totalStockholderEquity, last quarter 612.1m)
Debt / EBITDA = 22.28 (Net Debt 1.51b / EBITDA 67.9m)
Debt / FCF = 68.67 (Net Debt 1.51b / FCF TTM 22.0m)
Total Stockholder Equity = 611.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.01% (Net Income 280k / Total Assets 2.02b)
RoE = 0.05% (Net Income TTM 280k / Total Stockholder Equity 611.0m)
RoCE = 0.18% (EBIT 1.93m / Capital Employed (Equity 611.0m + L.T.Debt 475.1m))
RoIC = 0.08% (NOPAT 1.30m / Invested Capital 1.58b)
WACC = 3.07% (E(393.3m)/V(1.94b) * Re(11.84%) + D(1.55b)/V(1.94b) * Rd(1.25%) * (1-Tc(0.32)))
Discount Rate = 11.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -74.54 | Cagr: -1.32%
[DCF] Terminal Value 77.97% ; FCFF base≈13.4m ; Y1≈15.3m ; Y5≈22.5m
[DCF] Fair Price = N/A (negative equity: EV 339.0m - Net Debt 1.51b = -1.17b; debt exceeds intrinsic value)
EPS Correlation: -88.54 | EPS CAGR: -43.15% | SUE: 0.06 | # QB: 0
Revenue Correlation: -59.53 | Revenue CAGR: -1.53% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-07-31): EPS=0.38 | Chg30d=-1.72% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-10-31): EPS=0.83 | Chg30d=+15.74% | Revisions=+50% | Analysts=3
EPS current Year (2027-01-31): EPS=1.63 | Chg30d=+6.09% | Revisions=+50% | GrowthEPS=+36.7% | GrowthRev=+4.1%
EPS next Year (2028-01-31): EPS=2.28 | Chg30d=+7.90% | Revisions=+50% | GrowthEPS=+40.0% | GrowthRev=+2.9%
[Analyst] Revisions Ratio: +64% (up=10, down=1)